ESR1 and endometrial cancer: The first study published in endometrial cancer with the combination of letrozole and ribociclib, a third generation CDK4/6 inhibitor, showed that out of 20 ER+ endometrial cancer patients, 55% of patients were still on treatment at 12 weeks and 35% at 24 weeks.